These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 1637660)
1. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Lemaire L; Malet-Martino MC; de Forni M; Martino R; Lasserre B Br J Cancer; 1992 Jul; 66(1):119-27. PubMed ID: 1637660 [TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity of 5-fluorouracil: a question of formulation]. Lemaire L; Arellano M; Malet-Martino MC; Martino R; De Forni M Bull Cancer; 1994 Dec; 81(12):1057-9. PubMed ID: 7742593 [TBL] [Abstract][Full Text] [Related]
3. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Arellano M; Malet-Martino M; Martino R; Gires P Br J Cancer; 1998; 77(1):79-86. PubMed ID: 9459149 [TBL] [Abstract][Full Text] [Related]
4. The tris formulation of Fluorouracil is more cardiotoxic than the sodium-salt formulations. Lemaire L; Maletmartino M; Martino R; Deforni M; Lasserre B Oncol Rep; 1994 Jan; 1(1):173-4. PubMed ID: 21607331 [TBL] [Abstract][Full Text] [Related]
5. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche). Lemaire L; Malet-Martino MC; Longo S; Martino R; de Forni M; Carton M Lancet; 1991 Mar; 337(8740):560. PubMed ID: 1671927 [No Abstract] [Full Text] [Related]
6. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Arellano M; Malet-Martino M; Martino R; Spector T Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165 [TBL] [Abstract][Full Text] [Related]
7. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR). Tamatsu H; Nakazawa M; Imai S; Watari H Jpn J Pharmacol; 1984 Apr; 34(4):375-9. PubMed ID: 6233441 [TBL] [Abstract][Full Text] [Related]
8. Hydrolytic pathway of 5-fluorouracil in aqueous solutions for clinical use. Legay R; Massou S; Azéma J; Martino R; Malet-Martino M J Pharm Biomed Anal; 2014 Sep; 98():446-62. PubMed ID: 25038499 [TBL] [Abstract][Full Text] [Related]
9. A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Loqueviel C; Malet-Martino M; Martino R Cell Mol Biol (Noisy-le-grand); 1997 Jul; 43(5):773-82. PubMed ID: 9298599 [TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients. Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449 [TBL] [Abstract][Full Text] [Related]
11. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism. Spasojević I; Zakrzewska J; Bacić GG Ann N Y Acad Sci; 2005 Jun; 1048():311-20. PubMed ID: 16154943 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Matsubara I; Kamiya J; Imai S Jpn J Pharmacol; 1980 Dec; 30(6):871-9. PubMed ID: 7241861 [TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials. Lukaschek J; Nufer M; Maurer D; Asanger M; Honegger H; Widmer L; Malet-Martino M; Legay R; Martino R J Clin Oncol; 2004 Dec; 22(24):5022-5. PubMed ID: 15611524 [No Abstract] [Full Text] [Related]
14. Isolation of an aldehyde dehydrogenase involved in the oxidation of fluoroacetaldehyde to fluoroacetate in Streptomyces cattleya. Murphy CD; Moss SJ; O'Hagan D Appl Environ Microbiol; 2001 Oct; 67(10):4919-21. PubMed ID: 11571203 [TBL] [Abstract][Full Text] [Related]
15. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Akhtar SS; Salim KP; Bano ZA Oncology; 1993; 50(6):441-4. PubMed ID: 8233284 [TBL] [Abstract][Full Text] [Related]
16. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump. Fournet A; Gilard V; Malet-Martino M; Martino R; Canal P; De Forni M Cancer Chemother Pharmacol; 2000; 46(6):501-6. PubMed ID: 11138464 [TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. de Forni M; Malet-Martino MC; Jaillais P; Shubinski RE; Bachaud JM; Lemaire L; Canal P; Chevreau C; Carrié D; Soulié P J Clin Oncol; 1992 Nov; 10(11):1795-801. PubMed ID: 1403060 [TBL] [Abstract][Full Text] [Related]
18. Increased iron content in rat myocardium after 5-fluorouracil chronic administration. Millart H; Kantelip JP; Platonoff N; Descous I; Trenque T; Lamiable D; Choisy H Anticancer Res; 1993; 13(3):779-83. PubMed ID: 8317911 [TBL] [Abstract][Full Text] [Related]
19. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Cwikiel M; Zhang B; Eskilsson J; Wieslander JB; Albertsson M Scanning Microsc; 1995 Jun; 9(2):561-76. PubMed ID: 8714749 [TBL] [Abstract][Full Text] [Related]
20. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Hull WE; Port RE; Herrmann R; Britsch B; Kunz W Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]